Dr. Cinnamon Bidwell, PhD, Cannabis Psychopharmacology and Harm Reduction: Empirical Investigations Using Legal Market Products

October 2022

Dr. Cinnamon Bidwell’s primary research focus is translational studies investigating the effects of abused drugs and how these effects impact psychological and physical health acutely and chronically. For over a decade, she has been building on her training in studies of drug dependence, neurobehavior, behavioral genetics, and co-occurring psychiatric disorders. She has expertise in human laboratory studies on cannabis, cannabinoids, alcohol, and nicotine, and maintains research projects in the underlying factors that contribute to successful clinical treatment of psychiatric and substance use conditions. Her current research investigates the direct neurobiological effects of drugs of abuse, including high potency marijuana and cannabinoids in psychiatric and medical populations and the direct physiological and behavioral effects of cannabinoids as they pertain to both their abuse potential and potential therapeutic effects in observational as well as human laboratory studies.

Dr. Bidwell has published over 70 scientific publications and two book chapters on the neurobiology of substance abuse and its overlap with psychiatric disorders. She has received Early Career awards from premier professional societies including the American Psychological Association and the College on Problems of Drug Dependence, and is regularly invited to speak at national and international scientific meetings. Dr. Bidwell’s research is primarily funded by the National Institutes of Health and the state of Colorado.

Previous Webinars

Michael Petersen

Apr 15, 2026 11:00 AM Mountain Time

Trait Modifications in Cannabis Through Engineering and Editing

Michael Petersen has over 40 years of experience as a researcher and mentor in the plant biotech space. He worked for 10 years at Agracetus, a small startup in Wisconsin and then 20 years as a Senior Fellow with Monsanto. Mike stayed […]

Read More »

Francesca Filbey, PhD

Apr 9, 2026 01:00 PM Mountain Time

Understanding Cannabis Use Disorder Through Neuroimaging and Behavior

Francesca Filbey is a Professor and Director of the NeuroImaging of Reward Dynamics Laboratory at the Center for BrainHealth, School of Behavioral and Brain Sciences at The University of Texas at Dallas, and an Adjunct Associate Professor at the University of Texas […]

Read More »

Travis Higginbotham

March 25 at 11:00 AM (MDT)

Turning Science into Cash Flow. Crop production performance and ROI analysis driven by crop science.25

Travis Higginbitham is the Founder & CEO of Due Diligence Horticulture (DDH). He is a horticultural and operations executive with deep experience leading controlled-environment agriculture, cannabis, and ornamental production businesses through innovation, growth, transition, and turnaround. Mr. […]

Read More »

Dr. Yan Wang

12 March, 1:00 PM MST

Real-time and long-term effects of medical marijuana on older adults with chronic pain: Early findings from a prospective cohort study.

 

Yan Wang is an Associate Professor of Epidemiology at the University of Florida (UF). Her research interests focus on leveraging advanced technologies and methods (e.g., wearable sensors, ecological momentary assessment/EMA) to improve […]

Read More »

Igor Grant, M.D. and Thomas Marcotte, Ph.D.

Thursday, February 12th at 1:00 PM MST

The UC San Diego Center for Medicinal Cannabis Research: Some Findings

Igor Grant, MD is Distinguished Professor, and Director of the Center for Medicinal Cannabis Research (CMCR) at the University of California San Diego (UCSD). Established in 2000, the CMCR has been at the forefront of advancing science and policy […]

Read More »

Almut Winterstein, PhD.

Jan 8, 2026 01:00 PM Mountain Time

Clinical research priorities gleaned real-world use patterns: the MEdical Marijuana Outcomes Research repositorY (MEMORY)

Almut Winterstein is Distinguished Professor and the Dr. Robert and Barbara Crisafi Chair for Medication Safety in the Department of Pharmaceutical Outcomes and Policy and in the Department of Epidemiology, and the founding Director of the […]

Read More »